Literature DB >> 19996386

On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans.

Meena Asmar1, Winnie Tangaa, Sten Madsbad, Kristine Hare, Arne Astrup, Anne Flint, Jens Bülow, Jens Juul Holst.   

Abstract

We investigated the role of glucose-dependent insulintropic polypeptide (GIP) in the regulation of gastric emptying (GE), appetite, energy intake (EI), energy expenditure (EE), plasma levels of triglycerides (TAG), and free fatty acids (FFA) in humans. First, 20 healthy males received intravenous infusion of GIP (0.8 pmol.kg(-1).min(-1)) or saline for 300 min during and after a fixed meal (protocol 1). GE was measured using paracetamol, appetite sensations using visual analog scales, EE using indirect calorimetry, and EI during a subsequent ad libitum meal (at 300 min). Next, 10 healthy males received intravenous infusions of Intralipid, glucose, or Intralipid plus glucose, with and without GIP (1.5 pmol.kg(-1).min(-1)) for 300 min (protocol 2). In protocol 1, GIP did not have any effect on GE, EI, EE, removal of TAG, or FFA and did not influence the subjective feeling of hunger, satiety, fullness or prospective food consumption compared with saline. In protocol 2, no difference was seen in the plasma TAG on Intralipid + GIP/saline and Intralipid + glucose + GIP/saline days. FFA concentrations were lower on Intralipid + glucose + GIP/saline days (P < 0.05) compared with Intralipid + GIP/saline days and on Intralipid + GIP day (P < 0.004) compared with Intralipid + saline day. Insulin increased on all GIP days compared with saline days (P < 0.05). In conclusion, while confirming its insulinotropic effects, these data suggest that GIP does not affect GE, appetite, energy intake, EE, or the clearance rate of the applied TAG formulation in humans. However, both insulin and GIP lower post-Intralipid FFA concentration, GIP probably via stimulation of insulin secretion, increasing FFA reesterification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996386     DOI: 10.1152/ajpendo.00639.2009

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  19 in total

1.  Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase.

Authors:  Sameer Mohammad; Lavoisier S Ramos; Jochen Buck; Lonny R Levin; Francesco Rubino; Timothy E McGraw
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 2.  Role of gut nutrient sensing in stimulating appetite and conditioning food preferences.

Authors:  Anthony Sclafani; Karen Ackroff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-21       Impact factor: 3.619

Review 3.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

4.  Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial.

Authors:  Jeremy Pettus; Dominic Reeds; Tricia S Cavaiola; Schafer Boeder; Michelle Levin; Garry Tobin; Edda Cava; Dung Thai; Jim Shi; Hai Yan; Edgar Bautista; John McMillan; Roger Unger; Robert R Henry; Samuel Klein
Journal:  Diabetes Obes Metab       Date:  2018-01-22       Impact factor: 6.577

5.  Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain.

Authors:  Randi Ugleholdt; Jens Pedersen; Maria Rosaria Bassi; Ernst-Martin Füchtbauer; Signe Marie Jørgensen; Hanne-Louise Kissow; Nikolaj Nytofte; Steen Seier Poulsen; Mette Marie Rosenkilde; Yutaka Seino; Peter Thams; Peter Johannes Holst; Jens Juul Holst
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

6.  Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans.

Authors:  Meena Asmar; Lene Simonsen; Sten Madsbad; Bente Stallknecht; Jens Juul Holst; Jens Bülow
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

7.  Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.

Authors:  Natasha C Bergmann; Asger Lund; Lærke S Gasbjerg; Emma C E Meessen; Maria M Andersen; Sigrid Bergmann; Bolette Hartmann; Jens J Holst; Lene Jessen; Mikkel B Christensen; Tina Vilsbøll; Filip K Knop
Journal:  Diabetologia       Date:  2019-01-25       Impact factor: 10.122

8.  Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects.

Authors:  M Asmar; L Simonsen; N Arngrim; J J Holst; F Dela; J Bülow
Journal:  Int J Obes (Lond)       Date:  2013-05-17       Impact factor: 5.095

9.  Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids.

Authors:  Özlem Gögebakan; Janin Andres; Katrin Biedasek; Knut Mai; Peter Kühnen; Heiko Krude; Frank Isken; Natalia Rudovich; Martin A Osterhoff; Ulrich Kintscher; Michael Nauck; Andreas F H Pfeiffer; Joachim Spranger
Journal:  Diabetes       Date:  2011-12-16       Impact factor: 9.461

10.  Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300.

Authors:  Filip K Knop; Mikkel Christensen
Journal:  Diabetes       Date:  2012-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.